The extraordinary diversity of HIV is a major barrier in the path of developing a vaccine. One way forward may be mosaic antigens—biometrically designed genes that maximize overlap between sequences used in the vaccine and circulating HIV-1 strains worldwide (pages 319–323 and 324–328).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fischer, W. et al. Nat. Med. 13, 100–106 (2007).
Barouch, D.H. et al. Nat. Med. 16, 319–323 (2010).
Santra, S. et al. Nat. Med. 16, 324–328 (2010).
Salazar-Gonzalez, J.F. et al. J. Exp. Med. 206, 1273–1289 (2009).
Celum, C. et al. Lancet 371, 2109–2119 (2008).
Buchbinder, S.P. et al. Lancet 372, 1881–1893 (2008).
Pitisuttithum, P. et al. J. Infect. Dis. 194, 1661–1671 (2006).
Rerks-Ngarm, S. et al. N. Engl. J. Med. 361, 2209–2220 (2009).
Liu, Y. et al. J. Virol. 83, 10821–10829 (2009).
Goonetilleke, N. et al. J. Exp. Med. 206, 1253–1272 (2009).
Li, F. et al. Curr. HIV Res. 5, 97–107 (2007).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Corey, L., McElrath, M. HIV vaccines: mosaic approach to virus diversity. Nat Med 16, 268–270 (2010). https://doi.org/10.1038/nm0310-268
Issue date:
DOI: https://doi.org/10.1038/nm0310-268
